Treatment approach for non-Hodgkin lymphoma patients since first biosimilars of rituximab approved in EU5.

112Background: Non-Hodgkin Lymphoma (NHL) is the tenth most common cancer in Europe. In 2017, the first biosimilars of rituximab were approved in Europe to treat NHL. Using real world data from Ipsos’ Global Oncology Monitor, this study explores prescription patterns of rituximab biosimilars in EU5 to determine if biosimilars are favoured over branded versions for certain patient types. Methods: An online multi-country, multi-centre medical chart review study of NHL patients; 97 physicians provided de-identified data on 640 patients treated with anti-cancer drugs in France (117), Germany (73), Italy (117), Spain (136) and UK (197) between July and September 2017. Physicians were geographically representative and screened for treatment involvement levels and number of patients managed per month. Reporting on patients seen in consultation, they provided date of diagnosis, current and historic treatment, and reasons for prescribing/discontinuing anti-cancer drug treatment. Data on patients treated with and w...